Multivariate predictors for the development of new or worsened hypertension
| Variable . | HR . | 95% CI . | P . |
|---|---|---|---|
| Age* | 1.01 | (1.00-1.02) | .06 |
| BMI* | 1.02 | (1.00-1.04) | .052 |
| Male | 1.01 | (0.82-1.24) | .95 |
| African American race | 0.81 | (0.47-1.39) | .44 |
| Prior DM | 1.13 | (0.84-1.52) | .41 |
| Prior CKD | 0.93 | (0.72-1.20) | .58 |
| Smoking status: current/previous vs never | 0.92 | (0.75-1.12) | .40 |
| Primary malignancy | .01† | ||
| CLL vs MCL | 1.13 | (0.76-1.69) | .53 |
| CLL vs other, including WM‡ | 1.64 | (1.17-2.28) | .004 |
| MCL vs other, including WM‡ | 1.44 | (0.88-2.36) | .15 |
| Concurrent anthracycline | 1.39 | (0.73-2.66) | .31 |
| CYP3A4 inhibitor | 1.80 | (1.25-2.59) | .002 |
| Baseline SBP by baseline HTN status interaction | <.001† | ||
| Baseline SBP if no baseline HTN, mm Hg | |||
| <100 | Reference | Reference | |
| 100-119 | 2.94 | (1.38-6.26) | .01 |
| 120-129 | 3.20 | (1.47-6.98) | .003 |
| 130-139 | 3.84 | (1.58-9.36) | .003 |
| Baseline SBP if precedent baseline HTN, mm Hg | |||
| <120 | Reference | Reference | |
| 120-129 | 0.62 | (0.37-1.05) | .07 |
| 130-139 | 0.95 | (0.62-1.44) | .80 |
| >139 | 0.44 | (0.29-0.65) | <.001 |
| Variable . | HR . | 95% CI . | P . |
|---|---|---|---|
| Age* | 1.01 | (1.00-1.02) | .06 |
| BMI* | 1.02 | (1.00-1.04) | .052 |
| Male | 1.01 | (0.82-1.24) | .95 |
| African American race | 0.81 | (0.47-1.39) | .44 |
| Prior DM | 1.13 | (0.84-1.52) | .41 |
| Prior CKD | 0.93 | (0.72-1.20) | .58 |
| Smoking status: current/previous vs never | 0.92 | (0.75-1.12) | .40 |
| Primary malignancy | .01† | ||
| CLL vs MCL | 1.13 | (0.76-1.69) | .53 |
| CLL vs other, including WM‡ | 1.64 | (1.17-2.28) | .004 |
| MCL vs other, including WM‡ | 1.44 | (0.88-2.36) | .15 |
| Concurrent anthracycline | 1.39 | (0.73-2.66) | .31 |
| CYP3A4 inhibitor | 1.80 | (1.25-2.59) | .002 |
| Baseline SBP by baseline HTN status interaction | <.001† | ||
| Baseline SBP if no baseline HTN, mm Hg | |||
| <100 | Reference | Reference | |
| 100-119 | 2.94 | (1.38-6.26) | .01 |
| 120-129 | 3.20 | (1.47-6.98) | .003 |
| 130-139 | 3.84 | (1.58-9.36) | .003 |
| Baseline SBP if precedent baseline HTN, mm Hg | |||
| <120 | Reference | Reference | |
| 120-129 | 0.62 | (0.37-1.05) | .07 |
| 130-139 | 0.95 | (0.62-1.44) | .80 |
| >139 | 0.44 | (0.29-0.65) | <.001 |
n = 562. Bold P values indicate statistically significant results.
WM, Waldenström’s macroglobulinemia.
Considered a continuous variable.
Omnibus P value (reflects overall variable effect).
Diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, graft-versus-host disease, and marginal-zone lymphoma.